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ABSTRACT
Background    Bone mineral densitometry has been 
proven to be a powerful tool for the diagnosis and treat-
ment of osteoporosis, which is increasing with aging of 
the population, but opportunities to perform bone min-
eral densitometry in elderly facility residents, who are 
at a high risk of fracture, are scarce. 
Methods    We measured the bone mineral density in 
315 residents of 5 care facilities for the aged in middle 
Tottori Prefecture from 2002 to 2006. We also evalu-
ated residents of an elderly nursing home with a history 
of fragility fracture and those with osteoporosis who 
were administered risedronate for its therapeutic effect. 
Results    The bone mineral density was less than 
70% of the young adult mean in 161 (51.1%) of the 315 
subjects (aged 83.1 ± 7.8 years), 149 (57.8%) of the 258 
women (83.9 ± 7.2 years), and 12 (21.1%) of the 57 men 
(79.8 ± 9.3 years). In the 13 subjects who were admin-
istered risedronate, the bone mineral density increased 
from 65.8 to 67.2% of the young adult mean from 
before to after the beginning of administration, but it 
decreased in the control group (n = 9). In those admin-
istered risedronate, the urinary level of N-telopeptide (a 
marker for bone resorption) began to decrease 3 months 
after the beginning of the administration and showed a 
significant decrease after 11 months (n = 8) compared 
with the control group. The mean pain score based on 
the visual analogue scale showed significant reduction 
in the risedronate group compared with the control 
group. 
Conclusion    The bone mineral density was low in the 
facility residents and was less than 70% of the young 
adult mean in 57.8% of women and in 21.1% of men, 
more frequently than expected. Bone resorption and 
osteoporotic pain were suppressed by risedronate in os-
teopenic patients in such care facility. 
 
Key words    bone mineral density; care facilities for 
the aged; osteoporosis; risedronate; young adult mean 
 
 
In Japan, patients with osteoporosis are increasing an-
nually with the rapid aging of the population.1 Since 
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fracture due to osteoporosis leads to serious disabilities 
and a decrease in the quality of life, which may even 
be fatal,1 its management has emerged as an important 
social as well as medical issue.2–4 Osteoporosis used to 
be understood simply as aging of bone, but, in the late 
1980s, a few cohort studies involving local residents 
were also carried out in Japan, evaluating the incidence 
and effects of fracture due to osteoporosis, and indicat-
ing the importance of its prevention.1 Moreover, the 
concept of evidence-based medicine proposed in the 
1990s has also been adopted in the field of osteoporosis 
as a basic position of clinical medicine, and successive 
large-scale clinical trials with fracture as an endpoint 
have been conducted in Western countries since 1994. 
The spread of bone mineral analysis using a bone min-
eral analyzer and the availability of objective evaluation 
of the state of bone metabolism based on the measure-
ments of bone metabolic markers have markedly con-
tributed to this trend.3 As a result, in 1998, the Working 
Group of the Osteoporosis Study Group, Ministry of 
Health, Labour and Welfare Comprehensive Research 
on Longevity evaluated and organized information 
concerning anti-osteoporosis medications from objec-
tive viewpoints on the basis of the concept of evidence-
based medicine and prepared the Japanese Guidelines 
for the Prevention and Treatment of Osteoporosis.3, 4 
Thereafter, the necessity of the prevention and treat-
ment of osteoporosis has become widely recognized, 
and the guidelines have also been revised and widely 
accepted.4
 However, patients who can undergo bone mineral 
screening or measurement are limited to those who 
can visit departments such as the Departments of Or-
thopedics and Gynecology of a medical facility with 
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a bone mineral analyzer. The bone mineral density 
(BMD) has been shown to increase even in osteoporotic 
elderly people by making conscious efforts to walk,5 
and screening for osteoporosis is considered necessary 
for elderly care such as in long-term care facilities, in 
which many users are elderly people with a low activ-
ity level. The number of cases of hip fracture in Japan 
is estimated to exceed 120 thousand a year, about 10% 
of those who sustain the injury die within 1 year, and 
about 30% show declines in activities of daily living.6 
Also, skeletal deformities secondary to fracture cause a 
bedridden state or chronic lumbar pain, hump back, and 
a decrease in height, which impair activities of daily 
living and increase the necessity for long-term care.7, 8
 Many residents of care facilities are elderly people 
at a constant risk of fracture associated with falling, 
etc., and its prevention is very important. The evaluation 
of factors related to the bone strength as well as lifestyle 
and living environment is necessary for the prevention 
of fracture. In this study, the prevalence of osteoporosis 
was investigated in residents of long-term care facilities 
in middle Tottori Prefecture and the effect of therapeu-
tic intervention was evaluated in those who have few 
chances to be prescribed.
 
SUBJECTS AND METHODS
This study was carried out with approval (approval num-
ber 2301) by the Ethics Committee of Tottori University.
 
Prevalence of osteoporosis
The study was carried out between 2002 and 2006 in 
315 who consented to cooperate in the study of 450 resi-
dents of 5 care facilities for the aged in middle Tottori 
Prefecture. The total capacity of 8 facilities were 572 in 
maximal number in the same district, residents of rest 3 
facilities were not requested because of the lack of per-
mission from the head of these facilities.
 The BMD was measured using an ultrasound bone 
mineral densitometer (AOS-100NW, Hitachi-Aloka 
Medical, Tokyo, Japan) in the right calcaneus. This den-
sitometer was convenient to use at care facilities for the 
aged, because it required a short time for measurement, 
permitted dry measurement without using water, and 
needed no special facility as it emitted no radiation.
 For comparison of the BMD with middle-aged to 
elderly residents of the same area in middle Tottori Pre-
fecture, it was also measured in those who underwent 
comprehensive health screening at Hospital A and con-
sented to the measurement (using an ultrasound bone 
mineral densitometer, Benus III, Ishikawa Seisakusho, 
Hakusan, Japan).
 In 1996, the Japanese Society for Bone and Mineral 
Research proposed diagnostic criteria for osteoporosis 
by taking the BMD into consideration, and set cutoff 
values at < 70% of the mean BMD of those aged 20 to 
44 years (the young adult mean; YAM) for osteoporosis 
and 70 to 80% of the YAM for low BMD concerning 
Japanese women.9 In the 2000 revision, the cutoff value 
for the diagnosis of osteoporosis was also evaluated for 
men, and it was concluded that about 70% of the YAM 
was appropriate for the discrimination of a high-risk 
group for fracture in men as well as women.10 We ad-
opted this criteria to detect the prevalence of osteoporo-
sis in the residents of care facilities.
 
Effects of pharmacotherapy
The effects of pharmacotherapy were evaluated in 
the residents of a nursing home for the aged in middle 
Tottori Prefecture (Nursing Home B, one of 5 facili-
ties). The BMD was measured using an ultrasound bone 
densitometer (AOS-100NW, Hitachi-Aloka Medical) 
in the right calcaneus. As a treatment, sodium rise-
dronate (Benet, Takeda Pharmaceutical, Tokyo) was 
administered at 2.5 mg (once daily) to those with a his-
tory of fragility fracture and those with a BMD < 70% 
of YAM, and those who consented were followed up. 
Residents in Nursing Home B with same conditions as 
treated patients and those who consented to non-treat-
ment were also followed up as the control. Risedronate 
is expected to reduce bone resorption11, 12 and improve 
low back pain even in residents without vertebral frac-
tures.13
 Biological indices that specifically reflect bone 
metabolism have been confirmed to be useful as bone 
metabolic markers for the evaluation of bone turnover 
in bone remodeling, classification of disease types, and 
evaluation of therapeutic effects in metabolic bone dis-
orders such as osteoporosis.14–16 The measurement of 
the urinary levels of deoxypyridine and cross-linked N 
telopeptide of type I collagen (NTX) for osteoporosis 
began to be covered by insurance in December 1999. In 
this study, the urinary excretion of the bone resorption 
marker NTX was measured as an index of the thera-
peutic effect every 3 months for about 1 year. The mea-
surement, commissioned to SRL (Tokyo, Japan), was 
carried out by enzyme-linked immunosorbent assay. 
For evaluation of the urinary NTX level, the value was 
corrected for the creatinine level [creatinine-corrected 
NTX level = (NTX concentration/creatinine concentra-
tion) × 11.3] in consideration of the effect of the renal 
function. 
 The number of fracture cases was investigated by 
preparing a check sheet and obtaining cooperation of 
the staff of Nursing Home B. As for physical findings, 
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changes in the blood pressure were investigated using 
medical records. Pain was evaluated by quantification 
using Huskisson’s visual analog scale17 (VAS; 0 mm = 
no pain, 100 mm = worst pain possible).
 
Statistics 
Data of the 2 groups were compared using Student’s t-
test.
  
RESULTS
Prevalence of osteoporosis 
The 315 subjects consisted of 57 men (mean age: 79.8 ± 
9.3 years, range: 58–97 years) and 258 women (83.9 ± 7.2 
years, range: 53–100 years). The approximation curve 
of the relationship between the BMD as the percent-
age of the YAM and age was y = –0.2762x + 92.69 in 
women and y = –0.1321x + 87.667 in men (Fig. 1).  
 The BMD was < 70% of the YAM in 161 (51.5%) 
of the 315 subjects, 149 (57.8%) of the 258 women, and 
12 (21.1%) of the 57 men. The percentage of those in 
whom the BMD was < 70% of the YAM was about 2.4-
fold higher in women. As shown in the right of Fig. 2, 
in those who underwent comprehensive health screen-
ing at Hospital A, it was < 70% of the YAM in only 1 
(1.1%) of all 91 subjects, 1 (1.3%) of the 78 women and 
none (0%) of the 13 men. The relationship between the 
BMD as the percentage of the YAM, the rate of BMD 
< 70% of the YAM and age are shown also in Table 1. 
Fig. 1. BMD in facility residents. The BMD of the right calca-
neus in 315 residents of 5 care facilities for the aged is expressed 
as the percentage of the YAM (vertical axis) and plotted against 
age (horizontal axis). In women ( ), the approximation line is y = 
–0.2762x + 92.69 (solid line). In men ( ), the approximation line 
is y = –0.1321x + 87.667 (dashed line). BMD, bone mineral den-
sity; YAM, young adult mean. 
Fig. 2. Percentage of those with a BMD < 70% of the YAM in 
facility residents and health screenees. The left graph shows 
the percentages of those with a BMD < 70% of the YAM in all 
(51.1%, grey column), female (57.8%, white column) and male 
(21.1%, black column) facility residents. The right graph shows 
the percentages in all (1.1%), female (1.3%) and male (0%) health 
screenees. BMD, bone mineral density; YAM, young adult mean.
The difference between the BMD in facility residents 
and in health screenees (control) is apparent even in the 
same age groups.
 
Effects of pharmacotherapy 
In the subjects at Nursing Home B, the administration 
of sodium risedronate was recommended to 14 and ini-
tiated in 13 (2 men and 11 women with a mean age of 
83.0 ± 5.3 years, range: 77–91 years). The patient’s re-
cords showed that all patient had good compliance with 
their prescribed regimen. Fourteen similar residents 
(1 men and 13 women with a mean age of 87.6 ± 5.5 
years, range: 83–100 years) who consented were allo-
cated to the control. The BMD in the patients in whom 
it could be measured before and after the treatment (n = 
6) was 65.8 and 67.2% of the YAM, respectively (Fig. 3). 
Its changing rate is +2.0 ± 2.0% in the treated subjects 
and –3.5 ± 2.2% in the controls (n = 9) (P = 0.06).
 Of the patients administered sodium risedronate, 
urine samples could be obtained during the treatment 
period from 8. The urinary NTX level (creatinine-
corrected) decreased significantly 3 and 11 months after 
the beginning of the administration compared with the 
pre-administration value and was significantly lower 
than in the control group after 11 months (Fig. 4).
 During the observation period, no fracture occurred 
in the treated or control group. The mean pain score 
on the VAS decreased by 16.0 ± 5.8 mm in the treated 
group but showed slight decrease by 2.3 ± 4.1 mm in 
the control group. There is a significant difference be-
tween these values (P < 0.05).
 The mean systolic blood pressure was 126.4 ± 4.1 
mmHg before and 125.7 ± 4.5 mmHg after the ad-
ministration in the treated group. In the control group, 
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Fig. 3. Changes in the BMD as a percentage of the YAM between 
before and after the administration of sodium risedronate. The left 
bar graph shows the mean BMD as a percentage of the YAM in 
the risedronate-treated group before (left) and after (right) the ad-
ministration (n = 6). The right graph shows the mean values in the 
control group before (left) and after (right) the same observation 
period (n = 9). Data are expressed as mean ± SEM. BMD, bone 
mineral density; YAM, young adult mean.
however, it had somewhat increased from 125.3 ± 4.6 
mmHg to 132.3 ± 4.0 mmHg at the end of the observa-
tion period, without significant difference in changes 
between the 2 groups.. 
 
Table 1. BMD and number of those < 70%YAM by age group
 Age group (yr)
 50–59 60–69 70–79 80–89 90–99 100–109 Total
Residents
 Total number 2  15  74  155  68   1  315
 BMD (%YAM) 76 ± 12.7 77.8 ± 9.6* 73.3 ± 8.6* 69.9 ± 9.0 68.9 ± 7.3  70
 < 70% YAM 1 (50%) 2 (13.3%) 26 (35.1%) 85 (54.8%) 47 (69.1%) 0 (0%)
 Female 1  8  55  133  60  1  258
 BMD (%YAM) 85  75.1 ± 7.8* 71.8 ± 7.3 68.7 ± 7.5 68.1 ± 6.2   70 
 < 70%YAM 0 (0%) 2 (25%) 23 (41.8%) 81 (60.9%) 43 (71.7%)  0 (0%)
 Male 1  7  19  22  8  0  57
 BMD (%YAM) 67  80.9 ± 11 77.7  ± 10.7 76.9 ± 13.7 74.5 ± 11.9
 < 70%YAM 1 (100%) 0 (0%) 3 (15.8%) 4 (18.2%) 4 (50%) 0 (0%)
Controls
 Total number  40  4  3         47
 BMD (%YAM)  93.4 ± 12.9  93.4 ± 11.6  88.6 ± 3.1
 < 70% YAM 1 (2.5%)   0 (0%)  0 (0%) 
 Female  34  4  1        39
 BMD (%YAM) 92.6 ± 12.9 93.4 ± 11.6 88.4
 < 70% YAM  1 (2.9%)  0 (0%) 0 (0%)  
 Male  6  0   2           8
 BMD (%YAM)   97.8 ± 13.3  –  88.8 ± 4.3
 < 70% YAM 0 (0%) –  0 (0%) 
Residents: residents in 5 care facilities for the aged. Controls: health screenees at Hospital A. 
< 70%YAM, number of subjects in whom the BMD is < 70% of the YAM; BMD (%YAM), bone mineral density as the percentage of the 
YAM (%YAM); YAM, young adult mean (age: 20–44 years).
*P < 0.05 compared with the values in control.
DISCUSSION
There are many reports describing the BMD in the el-
derly patients or elderly community residents. However, 
We have little knowledge about BMD of the aged in 
the care facilities especially in the Tottori Prefecture 
due to lack of chances to measurement. It is the first 
report concerning the BMD for such facility residents 
in Tottori prefecture. In the present study, we showed 
that the BMD was lower in older subjects, as was gen-
erally expected in the residents of 5 care facilities for 
the aged. Fujiwara et al. evaluated bone mineral den-
sitometry data of 3,248 persons among the subjects 
of an epidemiological study selected from citizens of 
Hiroshima and Nagasaki Cities and reported, according 
to the diagnostic criteria of 1996, that the prevalence of 
osteoporosis was 24% (BMD in the lumbar vertebra) 
and 27% (BMD in the hip) in women aged 50 years and 
above.18 In males aged 50 years and above, also, they 
reported that 3.2% were diagnosed with osteoporosis 
with a cutoff BMD of < 70% of the YAM (lumbar ver-
tebra).18 It was low in more women than men, showing 
a gender difference. Since a gender difference similar to 
that observed in this study has been reported in many 
previous regular studies,19 Moreover, from the gender 
and age distribution of the prevalence of osteoporosis, 
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Fig. 4. Changes in the creatinine-corrected urinary cross-linked 
N telopeptide of type I collagen (NTX) level. Changes in the 
creatinine-corrected urinary NTX level after the administration 
of sodium risedronate at 2.5 mg are shown as a ratio of the value 
before administration (= 1). The values in the group administered 
sodium risedronate ( ) showed significant decreases after 3 and 
11 months ( ) compared with the pre-administration value (n = 8). 
The values in the control group ( ) also fluctuated but showed no 
significant change compared with the pre-administration value (n 
= 7). The urinary NTX concentration did not differ significantly 
between the risedronate-treated and control groups before the ad-
ministration but differed significantly after 11-month administra-
tion (†). Data are expressed as mean ± SEM.
Yamamoto reported that the prevalence of osteoporosis 
was increasing with age in both men and women and 
that it was about 3-fold higher in women than in men.20 
In our study, also, the prevalence of osteoporosis in the 
facility residents was about 2.4-fold higher in women 
than in men. In our subjects, women were predominant, 
accounting for 81.9%. This may be related to very low 
bone mass of this study.
 The percentage of those in whom the BMD of the 
lumbar vertebra was < 70% of the YAM among women 
aged 50 years and above, calculated from the popula-
tion in 2000 estimated by the Ministry of Health, Labor 
and Welfare was reported to be 29.2%.3 The percentage 
of those in whom the BMD of the calcaneus was < 70% 
of the YAM in women aged 50 years and above among 
the subjects of this study was about 57.8%, and this high 
frequency is suspected to be due to the presence of un-
derlying diseases and the consequent low activity level. 
Yamazaki et al. reported that the BMD increases due to 
suppression of bone turnover in postmenopausal women 
regularly practicing outdoor walking compared with 
those with no such habit.5 It has also been reported that 
the decrease in the BMD during a 10-year period was 
correlated with a decrease in activities of daily living in 
people aged 60 years and above.21 Considering these re-
ports, the low bone mass observed in our subjects may 
have been associated with a low activity level as a char-
acteristic of the facility residents or combined effects of 
multiple factors. Concerning Western populations re-
sembling the subjects of our study, there is also a report 
that osteoporosis was observed in 47% of the postmeno-
pausal women (mean age: 79 ± 10 years) admitted to a 
nursing home who underwent BMD measurements.22 
Compared with this value, also, the prevalence of osteo-
porosis in our subjects (57.8%) was high.
 However, the prevalence of osteoporosis was mark-
edly lower in the health screenees than in the facility 
residents, probably because the health screenees were 
more active and younger. Therefore, to detect osteopo-
rosis, it is considered necessary to screen those consult-
ing for medical services other than a comprehensive 
health checkup. Also, as the subjects of this study were 
facility residents, investigation of, and comparison with, 
the elderly living at home are considered necessary.
 Recently, a nation-wide survey in Japan revealed 
rapid increases in hip fracture over the last 10 years, and 
the necessity of treatment for osteoporosis and measures 
to prevent falls as well as appropriate treatment for hip 
fracture has been suggested.23 In Japan, bisphosphonate 
is most widely known and studied among drugs for the 
treatment of osteoporosis.1 Risedronate is a bisphos-
phonate which reduces resorption and bone turnover 
by inhibiting osteoclast activity. Risedronate has been 
shown to increase BMD and inhibit vertebral and hip 
fractures. Then, bisphosphonate preparations including 
sodium risedronate have been administered to patients 
with osteoporosis alone,24 those with osteoporosis and 
vertebral fracture,11, 12 and those after stroke,25, 26 and 
their effectiveness for fracture prevention and cost-
effectiveness have been evaluated. Among these stud-
ies, Ding et al.27 reported that the cost-effectiveness 
of risedronate was poor in Japanese women aged 55 
years or above and even those aged 70 years or above if 
they have no history of vertebral fracture. However, on 
the basis of the results of a survey of residents of vari-
ous care facilities including homes for elderly people 
with dementia in the United Kingdom, Aspray et al.28 
contended that the risk of fracture at these facilities is 
ignored and that treatment is necessary. As far as we 
searched, effect of risedronate has not been examined 
in the residents in care facilities except for hospitalized 
disabled patients after stroke in Japan.25 In this regard, 
it appears reasonable that patients who consented were 
treated at our study in care facilities for prevention 
against new fracture, and reduction of pain13 concern-
ing low bone mass.
 There is a report that bisphosphonate increases the 
BMD but its preventive effect on postmenopausal frac-
ture is insufficient without sufficient drug compliance,29 
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and a significant correlation between the compliance 
with bisphosphonate therapy and risk of fracture has 
been noted.30 Particularly, drug compliance is likely to 
be poor when patients are asymptomatic, as in osteopo-
rosis, and marked compliance has been reported to be 
related to BMD measurement after the administration 
and being nursing home residents,31 both of which ap-
plied to our subjects. In this study, as a result of check-
ing the administration using a check sheet, compliance 
with the risedronate therapy was satisfactory. Therefore, 
while the BMD decreased by 3.5% of the YAM in the 
control group, it increased by 2% in the treated group, 
probably because of the effect of the administration. 
 A long time is needed to evaluate the fracture-
preventive effect, which is the ultimate objective of 
treatment for osteoporosis, and the BMD and bone 
metabolic markers, which suggest the course of its 
changes, are monitored as short-term indices. Bone 
formation and bone resorption play key roles in main-
taining the bone mass and quality. There are different 
markers of bone formation and resorption, and they are 
useful because their measurements by blood tests or 
urinalysis permit simple evaluation of the state of bone 
metabolism.16 If bone turnover is enhanced, aggressive 
treatment is considered necessary, because not only is 
the decrease in the BMD accelerated, but also the risk 
of fracture is increased regardless of the BMD.32 Hu-
man bone is composed primarily of calcium phosphate 
and type I collagen, and if bone is decomposed by 
osteoclasts, NTX, a degradation product of type I col-
lagen, is excreted into blood and, then, urine. Therefore, 
the degree of bone decomposition can be evaluated by 
measuring urinary NTX, and the urinary NTX level is 
used for the diagnosis of osteoporosis and its responses 
to treatment.15, 16 The urinary NTX level, which reflects 
bone resorption, has been reported to be inversely cor-
related with the BMD, to be reduced by antiresorptive 
therapies, and to be more sensitive than the serum NTX 
level.33 While the BMD is an index representing the 
results of past bone metabolism, the NTX level repre-
sents the present degree of bone resorption and predicts 
decreases in the BMD in the near future.15 Thus, people 
with a high NTX level are considered to reach a high-
risk zone for fracture earlier than those with about the 
same BMD but a low NTX level.15 Therefore, people 
with a low bone mass and low NTX, in particular, may 
require more aggressive treatment. In treating osteopo-
rosis or reducing the risk of fracture, a bone turnover 
marker is considered to be significant as an intermediate 
endpoint in an early period of treatment before changes 
in the BMD become clear.34 Eastel et al.35 reported not 
only that early changes in the bone-turnover marker 
level were predictive of changes in the BMD, but also 
that changes in the urinary NTX level 3 to 6 months 
after the beginning of treatment with risedronate, etc., 
were correlated with decreases in the risk of vertebral 
fracture. In this study, the creatinine-corrected urinary 
NTX level decreased in the group treated with sodium 
risedronate, suggesting that the drug suppressed bone 
turnover and reduced the risk of fracture. 
 Since the administration of sodium risedronate had 
been reported to be useful for improving the quality 
of life24 as well as preventing spinal fracture and the 
recurrence of femoral fracture,36 similar effects were 
expected in this study. Indeed, the significant difference 
between the decrease in the pain score in the control 
group and in the treated group may have been due to 
improvement of pain induced by osteoporosis or dis-
orders associated with a low bone mass. However, no 
fracture was observed during the observation period in 
the treated or control group. This is considered to be 
related to the small number of subjects and short obser-
vation period. 
 The systolic blood pressure was slightly increased 
in the control group. This increase in the systolic blood 
pressure may be related to a decrease in the BMD. This 
is because reports that a low Ca intake and decrease 
in the BMD associated with Ca loss were related to an 
elevation of the blood pressure37–39 and an increase in 
the arterial stiffness was correlated with a decrease in 
the BMD in hypertensive patients40 suggest a relation-
ship between a decrease in the BMD and an elevation 
of the blood pressure. However, as there is also a report 
that the BMD was not associated with hypertension,41 
further evaluation is necessary. 
 There are some limitations to our investigation. 
First, in this study, we used the criteria proposed in the 
diagnostic guideline 200010 to diagnose the osteoporo-
sis because this survey had been planned and performed 
between 2002 and 2006. In the 2012 revision of the 
guideline,42 for the definite diagnosis of osteoporosis, 
ultrasound bone mineral densitometry determined to be 
not appropriate. Second, the number of residents is too 
small, and especially to detect a pharmacological effect 
on the prevention of the bone fracture, the observation 
period is too short.  
The authors declare no conflict of interest.
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